Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee
The PST currently consists of 23 members from 16 countries and meets on a monthly basis. Currently, involving laboratories of diverse Subcommittee members, a pilot trial is conducted to define the next steps towards a comprehensive standardization trial.
These efforts aim to harmonize laboratory practices, support clinical trials, and facilitate regulatory approval processes, contributing significantly to the development and broader use of phage-based therapies.
Contact us if you have questions or comments to the phage susceptibility testing group.
We’ve prepared a short video to help you get familiar with the new layout and features.